David Gryska - Seagen Independent Director
| SGENDelisted Stock | USD 228.74 0.19 0.08% |
Director
Mr. David W. Gryska is an Independent Director of Seattle Genetics, Inc., since March 2005. From October 2014 through December 2018, Mr. Gryska served as Executive Vice President and Chief Financial Officer of Incyte Corporationrationration, a publiclytraded biopharmaceutical company. From May 2012 to December 2012, Mr. Gryska served as Chief Operating Officer and from August 2012 to December 2012, interim Chief Executive Officer of Myrexis Inc., a publiclytraded biotechnology company. From December 2006 to October 2010, he served as Senior Vice President and Chief Financial Officer of Celgene Corporationrationration. From October 2004 to December 2006, he was a principal at Strategic Consulting Group, where he provided strategic consulting to earlystage biotechnology companies. Mr. Gryska served at Scios, Inc., a biopharmaceutical company, as Senior Vice President and Chief Financial Officer from November 2000 to October 2004, and as Vice President of Finance and Chief Financial Officer from December 1998 to November 2000. Scios was acquired by Johnson Johnson in 2003. From 1993 to December 1998, he served as Vice President, Finance and Chief Financial Officer at Cardiac Pathways Corporationrationration, a medical device company which was later acquired by Boston Scientific Corporationrationration. Prior to Cardiac Pathways, Mr. Gryska served as a partner at Ernst Young LLP, an accounting firm. During his eleven years at Ernst Young LLP, he focused on technology industries, with an emphasis on biotechnology and healthcare companies since 2005.
| Age | 62 |
| Tenure | 19 years |
| Professional Marks | MBA |
| Phone | 425 527 4000 |
| Web | https://www.seagen.com |
Seagen Management Efficiency
The company has return on total asset (ROA) of (0.1294) % which means that it has lost $0.1294 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2793) %, meaning that it created substantial loss on money invested by shareholders. Seagen's management efficiency ratios could be used to measure how well Seagen manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 43.47 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Seagen Inc has a current ratio of 4.48, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Seagen until it has trouble settling it off, either with new capital or with free cash flow. So, Seagen's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Seagen Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Seagen to invest in growth at high rates of return. When we think about Seagen's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Michael Mayer | Ascendis Pharma AS | 59 | |
| Jacqualyn Fouse | Incyte | 56 | |
| Raymond Kurzweil | United Therapeutics | 70 | |
| Daniel Hume | TG Therapeutics | 51 | |
| Steven Paul | Alnylam Pharmaceuticals | 67 | |
| Lance Willsey | Exelixis | 56 | |
| Amy Schulman | Alnylam Pharmaceuticals | 57 | |
| Daniel Welch | Ultragenyx | 60 | |
| Kevin Starr | Alnylam Pharmaceuticals | 53 | |
| JeanPierre Bizzari | Halozyme Therapeutics | 63 | |
| Clay Siegall | Ultragenyx | 57 | |
| Marsha Fanucci | Alnylam Pharmaceuticals | 64 | |
| Richard Meier | Biomarin Pharmaceutical | 57 | |
| Randal Kirk | Halozyme Therapeutics | 63 | |
| Vincent Marchesi | Exelixis | 82 | |
| Albert Cha | Ascendis Pharma AS | 45 | |
| Rene Russo | X4 Pharmaceuticals | 42 | |
| Sinclair Dunlop | Apellis Pharmaceuticals | 46 | |
| James Daly | Madrigal Pharmaceuticals | N/A | |
| Katherine Klein | United Therapeutics | 61 | |
| Paul Schimmel | Alnylam Pharmaceuticals | 77 | |
Management Performance
| Return On Equity | -0.28 | |||
| Return On Asset | -0.13 |
Seagen Inc Leadership Team
Elected by the shareholders, the Seagen's board of directors comprises two types of representatives: Seagen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Seagen. The board's role is to monitor Seagen's management team and ensure that shareholders' interests are well served. Seagen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Seagen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Roger Dansey, Chief Medical Officer | ||
| Vaughn Himes, Executive VP of Process Sciences and Technical Operations | ||
| Daniel Welch, Independent Director | ||
| Felix Baker, Lead Independent Director | ||
| Nancy Simonian, Independent Director | ||
| Peggy Pinkston, IR Contact Officer | ||
| Charles Romp, Ex US | ||
| MS JD, Chief Officer | ||
| Darren Cline, Executive Vice President - Commercial | ||
| Eric Dobmeier, COO, Corporate Secretary | ||
| Todd Simpson, CFO and Principal Accounting Officer | ||
| Pinkston Peggy, Senior Director - Corporate Communications | ||
| David Gryska, Independent Director | ||
| David Caouette, VP Communications | ||
| Srinivas Akkaraju, Independent Director | ||
| Alpna Seth, Director | ||
| Matt Skelton, VP Marketing | ||
| Marc Lippman, Independent Director | ||
| Jonathan Drachman, Chief Medical Officer and Executive Vice President Research and Development | ||
| Jean Liu, Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary | ||
| Robert Lechleider, Senior Vice President - Clinical Development | ||
| Christopher Pawlowicz, Ex HR | ||
| Clay Siegall, Co-Founder, Chairman, CEO and Pres | ||
| Robin Taylor, Chief Commercial Officer | ||
| Dennis Benjamin, Senior Vice President - Translational Research | ||
| Roger MD, Pres RD | ||
| John Orwin, Director | ||
| John McLaughlin, Independent Director |
Seagen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Seagen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.28 | |||
| Return On Asset | -0.13 | |||
| Profit Margin | (0.33) % | |||
| Operating Margin | (0.35) % | |||
| Current Valuation | 42.06 B | |||
| Shares Outstanding | 188.66 M | |||
| Shares Owned By Insiders | 0.81 % | |||
| Shares Owned By Institutions | 88.82 % | |||
| Number Of Shares Shorted | 9.58 M | |||
| Price To Earning | 32.75 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. Note that the Seagen Inc information on this page should be used as a complementary analysis to other Seagen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Other Consideration for investing in Seagen Stock
If you are still planning to invest in Seagen Inc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Seagen's history and understand the potential risks before investing.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |